Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(1)
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Falling Comet
1940.5000
3.20
(
0.17
%)
NSE
Oct 15, 2025
15:31 PM
Volume:
636.8K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
07 Aug 2025
US FDA Approval
1940.50
0.17%
Result Update:Lupin
Buy:
Lupin Ltd.
by
Axis Direct
Target: 2400 | Upside : 23.7%
Target
Axis Direct
We recommend a BUY rating with a target price of Rs 2,500/share.
Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
More from Lupin Ltd.
Recommended
Market closes higher, Jindal Stainless plans Rs 1,325 cr capex for slag plant
Trendlyne Marketwatch |
15 Oct 2025, 04:02PM
Rural India is spending more, but household incomes haven’t caught up
The Baseline |
15 Oct 2025, 01:21PM
Lupin expects normalization by September quarter
|
17 Apr 2020